Publicação

Development and pre-clinical evaluation of a new HIV-1 vaccine concept

Ver documento

Detalhes bibliográficos
Resumo:New immunogens that elicit the production of broadly neutralizing antibodies (bNAbs) are needed to prevent and control HIV-1 epidemic. However, their induction by vaccination is still a difficult task. Prime-boost immunization strategies combining poxvirus with envelope glycoproteins constitutes a promising approach for an HIV-1 preventive vaccine as they provide strong immune responses. Recently, bNAbs against HIV-2 were elicited in mice using a Vaccinia vector-prime C2V3C3 polypeptide boost vaccination strategy. Thus, the main goal of this thesis was to determine if a similar strategy would elicit the production of bNAbs against HIV-1. The general aims of this thesis were: obtain and examine HIV-1 samples derived from Angolan isolates as a paradigm of the ancestral viruses we intended to use in a new type of vaccine, express envelope genes from Angolan and Portuguese isolates in Vaccinia virus and produce the autologous C2V3C3 recombinant polypeptides, investigate the immunogenicity of these immunogens in mice and rabbits using different regimens and quantify the respective cellular immune responses. In chapter 2, three full-length genomes from Angolan patients were sequenced and analyzed in order to better understand the origin and dynamics of HIV-1 in Angola. A pure subtype J, a subtype J with a small uncertain region and the first H/U/CRF02_AG recombinant were identified. Overall, these results supported the extraordinary genetic diversity of HIV-1 and confirm the ancestral presence of this subtypes in Angola. In chapters 3, gp120 glycoproteins expressed in Vaccinia virus, soluble gp120 and C2V3C3 polypeptides derived from several HIV-1 isolates from Angola and Portugal (clades B, C, CRF02_AG and J) were produced and used as immunogens in mice and rabbits (chapter 4). CRF02_AG based immunogens were able to elicit bNAbs against several heterologous HIV-1 tier 2 viruses and V3 region was found to be one of the main target of this immunogen. Antibody responses were associated with adequate Tfh and Tfr responses indicating that this strategy targeted the cellular subsets required for the induction of an effective NAb response. In conclusion, the results obtained suggest that the novel CRF02_AG based immunogens and primeboost immunization strategy may be able to induce the type of response intended in a preventive HIV-1 vaccine.
Autores principais:Calado, Rita
Assunto:Teses de doutoramento - 2018
Ano:2018
País:Portugal
Tipo de documento:tese de doutoramento
Tipo de acesso:acesso aberto
Instituição associada:Universidade de Lisboa
Idioma:inglês
Origem:Repositório da Universidade de Lisboa
_version_ 1866809780403699712
author Calado, Rita
author_facet Calado, Rita
author_role author
contributor_name_str_mv Taveira, Nuno, 1964-
Pereira, J. Moniz, 1949-
Repositório Científico de Acesso Aberto da ULisboa
country_str PT
creators_json_txt [{\"Person.name\":\"Calado, Rita\",\"Person.identifier.orcid\":\"0000-0002-2519-7917\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Taveira, Nuno, 1964-
Pereira, J. Moniz, 1949-
Repositório Científico de Acesso Aberto da ULisboa
datacite.creators.creator.creatorName.fl_str_mv Calado, Rita
datacite.date.Accepted.fl_str_mv 2018-01-01T00:00:00Z
datacite.date.available.fl_str_mv 2019-01-22T01:30:16Z
datacite.date.embargoed.fl_str_mv 2019-01-22T01:30:16Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Teses de doutoramento - 2018
datacite.titles.title.fl_str_mv Development and pre-clinical evaluation of a new HIV-1 vaccine concept
dc.contributor.none.fl_str_mv Taveira, Nuno, 1964-
Pereira, J. Moniz, 1949-
Repositório Científico de Acesso Aberto da ULisboa
dc.creator.none.fl_str_mv Calado, Rita
dc.date.Accepted.fl_str_mv 2018-01-01T00:00:00Z
dc.date.available.fl_str_mv 2019-01-22T01:30:16Z
dc.date.embargoed.fl_str_mv 2019-01-22T01:30:16Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://hdl.handle.net/10451/32686
dc.language.none.fl_str_mv eng
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv Teses de doutoramento - 2018
dc.title.fl_str_mv Development and pre-clinical evaluation of a new HIV-1 vaccine concept
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_db06
description New immunogens that elicit the production of broadly neutralizing antibodies (bNAbs) are needed to prevent and control HIV-1 epidemic. However, their induction by vaccination is still a difficult task. Prime-boost immunization strategies combining poxvirus with envelope glycoproteins constitutes a promising approach for an HIV-1 preventive vaccine as they provide strong immune responses. Recently, bNAbs against HIV-2 were elicited in mice using a Vaccinia vector-prime C2V3C3 polypeptide boost vaccination strategy. Thus, the main goal of this thesis was to determine if a similar strategy would elicit the production of bNAbs against HIV-1. The general aims of this thesis were: obtain and examine HIV-1 samples derived from Angolan isolates as a paradigm of the ancestral viruses we intended to use in a new type of vaccine, express envelope genes from Angolan and Portuguese isolates in Vaccinia virus and produce the autologous C2V3C3 recombinant polypeptides, investigate the immunogenicity of these immunogens in mice and rabbits using different regimens and quantify the respective cellular immune responses. In chapter 2, three full-length genomes from Angolan patients were sequenced and analyzed in order to better understand the origin and dynamics of HIV-1 in Angola. A pure subtype J, a subtype J with a small uncertain region and the first H/U/CRF02_AG recombinant were identified. Overall, these results supported the extraordinary genetic diversity of HIV-1 and confirm the ancestral presence of this subtypes in Angola. In chapters 3, gp120 glycoproteins expressed in Vaccinia virus, soluble gp120 and C2V3C3 polypeptides derived from several HIV-1 isolates from Angola and Portugal (clades B, C, CRF02_AG and J) were produced and used as immunogens in mice and rabbits (chapter 4). CRF02_AG based immunogens were able to elicit bNAbs against several heterologous HIV-1 tier 2 viruses and V3 region was found to be one of the main target of this immunogen. Antibody responses were associated with adequate Tfh and Tfr responses indicating that this strategy targeted the cellular subsets required for the induction of an effective NAb response. In conclusion, the results obtained suggest that the novel CRF02_AG based immunogens and primeboost immunization strategy may be able to induce the type of response intended in a preventive HIV-1 vaccine.
dirty 0
eu_rights_str_mv openAccess
format doctoralThesis
fulltext.url.fl_str_mv https://repositorio.ulisboa.pt/bitstreams/6dfdb847-d974-4cd1-b1a6-8ff3184bd51a/download
funding.funder.alternateName_str_mv FCT
funding.funder.identifier_str_mv http://doi.org/10.13039/501100001871
funding.funder.name_str_mv Fundação para a Ciência e a Tecnologia
id ul_c83c5cf8d4c4f77fa072e3345d5facf0
identifier.url.fl_str_mv http://hdl.handle.net/10451/32686
instacron_str ul
institution Universidade de Lisboa
instname_str Universidade de Lisboa
language eng
network_acronym_str ul
network_name_str Repositório da Universidade de Lisboa
oai_identifier_str oai:repositorio.ulisboa.pt:10451/32686
organization_str_mv urn:organizationAcronym:ul
person_str_mv Calado, Rita
Calado, Rita
https://www.ciencia-id.pt/AA18-62FA-B4B3
AA18-62FA-B4B3
http://orcid.org/0000-0002-2519-7917
0000-0002-2519-7917
publishDate 2018
reponame_str Repositório da Universidade de Lisboa
repository_id_str urn:repositoryAcronym:ul
service_str_mv urn:repositoryAcronym:ul
spelling engpt_PTNew immunogens that elicit the production of broadly neutralizing antibodies (bNAbs) are needed to prevent and control HIV-1 epidemic. However, their induction by vaccination is still a difficult task. Prime-boost immunization strategies combining poxvirus with envelope glycoproteins constitutes a promising approach for an HIV-1 preventive vaccine as they provide strong immune responses. Recently, bNAbs against HIV-2 were elicited in mice using a Vaccinia vector-prime C2V3C3 polypeptide boost vaccination strategy. Thus, the main goal of this thesis was to determine if a similar strategy would elicit the production of bNAbs against HIV-1. The general aims of this thesis were: obtain and examine HIV-1 samples derived from Angolan isolates as a paradigm of the ancestral viruses we intended to use in a new type of vaccine, express envelope genes from Angolan and Portuguese isolates in Vaccinia virus and produce the autologous C2V3C3 recombinant polypeptides, investigate the immunogenicity of these immunogens in mice and rabbits using different regimens and quantify the respective cellular immune responses. In chapter 2, three full-length genomes from Angolan patients were sequenced and analyzed in order to better understand the origin and dynamics of HIV-1 in Angola. A pure subtype J, a subtype J with a small uncertain region and the first H/U/CRF02_AG recombinant were identified. Overall, these results supported the extraordinary genetic diversity of HIV-1 and confirm the ancestral presence of this subtypes in Angola. In chapters 3, gp120 glycoproteins expressed in Vaccinia virus, soluble gp120 and C2V3C3 polypeptides derived from several HIV-1 isolates from Angola and Portugal (clades B, C, CRF02_AG and J) were produced and used as immunogens in mice and rabbits (chapter 4). CRF02_AG based immunogens were able to elicit bNAbs against several heterologous HIV-1 tier 2 viruses and V3 region was found to be one of the main target of this immunogen. Antibody responses were associated with adequate Tfh and Tfr responses indicating that this strategy targeted the cellular subsets required for the induction of an effective NAb response. In conclusion, the results obtained suggest that the novel CRF02_AG based immunogens and primeboost immunization strategy may be able to induce the type of response intended in a preventive HIV-1 vaccine.application/pdfpt_PTDevelopment and pre-clinical evaluation of a new HIV-1 vaccine conceptPersonalCalado, RitaDSpacehttp://dspace.org/items/bca88dd5-4b60-4441-93dd-eddfa6fa50efDSpacehttp://dspace.org/items/bca88dd5-4b60-4441-93dd-eddfa6fa50efAlmeida CaladoRita DiogoCiência IDhttps://www.ciencia-id.ptAA18-62FA-B4B3ORCIDhttp://orcid.org0000-0002-2519-7917Taveira, Nuno, 1964-Pereira, J. Moniz, 1949-HostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptURNurn:tid:1013759212019-01-22T01:30:16Z201820182018-01-01T00:00:00ZHandlehttp://hdl.handle.net/10451/32686http://purl.org/coar/access_right/c_abf2open accessTeses de doutoramento - 20185276561 bytesFundação para a Ciência e a TecnologiaDEVELOPMENT AND PRE-CLINICAL EVALUATION OF A NEW HIV-1 VACCINE CONCEPTCrossref Funder IDhttp://doi.org/10.13039/501100001871literaturehttp://purl.org/coar/resource_type/c_db06doctoral thesishttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/6dfdb847-d974-4cd1-b1a6-8ff3184bd51a/download
spellingShingle Development and pre-clinical evaluation of a new HIV-1 vaccine concept
Calado, Rita
Teses de doutoramento - 2018
status SINGLETON
subject.fl_str_mv Teses de doutoramento - 2018
title Development and pre-clinical evaluation of a new HIV-1 vaccine concept
title_full Development and pre-clinical evaluation of a new HIV-1 vaccine concept
title_fullStr Development and pre-clinical evaluation of a new HIV-1 vaccine concept
title_full_unstemmed Development and pre-clinical evaluation of a new HIV-1 vaccine concept
title_short Development and pre-clinical evaluation of a new HIV-1 vaccine concept
title_sort Development and pre-clinical evaluation of a new HIV-1 vaccine concept
topic Teses de doutoramento - 2018
topic_facet Teses de doutoramento - 2018
url http://hdl.handle.net/10451/32686
visible 1